PDA

View Full Version : Saneron ASIA to Initiate Clinical Trials for Amyotrophic lateral sclerosis (ALS)



Leif
11-13-2005, 11:18 AM
Saneron ASIA to Initiate Clinical Trials for Amyotrophic lateral sclerosis (ALS) and Stroke Using Proprietary HUCB Stem cell Technology


http://www.prleap.com/pr/19282/



News Released: November 13, 2005

(PRLEAP.COM) The first trial is for ALS known as Lou Gehrig’s Disease is designed to evaluate the safety and efficacy of potential treatments in order to bring new effective therapies to market. The Trials will begin early next year in India and Taiwan. The Asian team Leader will be Dr. Shinn-Zong (John) Lin M.D., Ph.D. Professor of Neurosurgery and Superintendent of Tzu Chi General Hospital in Hualien, Taiwan. The trials are set to start first in Taiwan in early 2006. Saneron India will begin accepting patients in spring of 2006 at the Stem Cell Center in Chennai, India. Saneron India will work closely with LifeCell, Asia CRYO-CELL Private Limited, and Shasun Chemicals & Drugs.

The Stroke Trials begin in may are planned to evaluate safety and efficacy of our UCORD stem cell suspension therapy in stroke patients.at the chennai based stem cell center. Stroke the third leading cause of death in the United States and second worldwide, 700,000 victims in the U.S. each year. The American Heart Association estimated the economic costs in the US at $56.8B in 2005.

About Saneron Asia
Saneron Asia is a Bio-Pharmaceutical stem cell therapeutic company focused on the Development and commercializing Saneron’s proprietary HUCB Stem cell and Sertoli cell technologies. Saneron Asia is focused on creating safe and efficacious clinical applications of HUCB for the early intervention and treatment of several devastating or deadly neurological and cardiac diseases and disorders by bringing new therapies to the Asian markets that improve people’s health and help to revolutionize medicine.

About Saneron India
Saneron India is a newly formed company headed by Mr Abaya Kumar has who will also be Saneron Asia`s Co-Chairman and the Leader of Asia CRYO-CELL. Saneron India will be headquartered in Chennai India and will establish specialized stem cell centers in major cities throughout India. Mr Kumar is also the Co-Managing Director of Shasun chemicals and drugs limited, the worlds largest manufacturer of the active pharmaceutical ingredient ibuprofen, providing Saneron India with expertise in research science, Good Manufacturing Practices (cGMP) and high quality systems. Saneron India is also establishing a proprietary, allogeneic bank of GMP manufactured HUCB stem cells suspensions designed for therapeutic applications for neurological and cardiac disorders.

About Saneron CCEL Therapeutics, Inc.
Saneron is a biotechnology R&D company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of CRYO-CELL International, Inc., Saneron is committed to providing readily available, non-controversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.

About Tzu Chi General Hospital
Tzu Chi, a United Nations affiliated NGO In 1979 Dharma Master Cheng Yen resolved to build a hospital that manifests itself in the form of love, even though she was short on funds and Medical Professionals. The master realized that illness often creates poverty and poverty often creates illness. Hualien Tzu Chi General Hospital was completed in August 1986 ,.The medical center has 926 beds and 38 departments manned by 275 doctors, 756 nurses, 369 medical technicians as well as 150 volunteers who are from various parts of the island on rotation basis. It treats about 1,650 outpatients and 135 emergency patients per day.


About Dr.Shinn-Zong (John) Lin, M.D., Ph.D.
Professor and Chairman of Neuro-Medical Scientific Center
Professor of Neurosurgery of Tzu Chi University
Superintendent, Tzu Chi General Hospital
Email: SZLIN@tzuchi.com.tw (SZLIN@tzuchi.com.tw)

For Further Information Please Contact:
Saneron Asia
Japanese Branch Office Preparations Room
Minato-ku, Tokyo Konan 2-15-1
Shinagawa Inter-city A ridge the 28th floor
2-1-5kamatari kazusa kisarazu chibasi
JAPAN
Incubation Center (during application)
TEL: 81-3-6717-4298
FAX: 81-3-6717-4141
info@saneron-asia.com (info@saneron-asia.com)
ATTN : Mrs Nakamura nakamura@saneron-asia.com (nakamura@saneron-asia.com)
Japan. Telephone: 81-90-5761-0229
www.saneron-asia.com (http://www.saneron-asia.com/)

Saneron India
Abhaya Kumar
Asia CRYO-CELL Private Limited
5 Vivekananda Street (Spur Tank Road)
Srinivasa Nagar, Chetput
Chennai 600 031
INDIA
Phone: +91-44-5206-5706
Fax : +91-44-5206-5726
Email : contactus@lifecellindia.com (contactus@lifecellindia.com)
www.lifecellindia.com (http://www.lifecellindia.com/)

Saneron CCEL Therapeutics Inc.
Nicole Kuzmin-Nichols, MBA
3802 Spectrum Blvd., Suite 145
Tampa, FL 33612
USA
Phone: 813-977-7664 x2
Fax: 813-435-2360
nkn@saneron-ccel.com (nkn@saneron-ccel.com)
www.saneron-ccel.com (http://www.saneron-ccel.com/)

Buddhist Tzu Chi General Hospital
www.tzuchi.com.tw (http://www.tzuchi.com.tw/)
Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.